Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2007-10-26 M&A Activity
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
M&A Activity 2007
M&A Activity Classification · 99% confidence The document is a press release dated October 26, 2007, providing an update on a previously announced acquisition (Orexo acquiring Biolipox). Crucially, the text states: "Orexo lämnar idag ytterligare information kring det planerade förvärvet av Biolipox genom en uppdaterad presentation (se bifogad bilaga). Presentationen finns även tillgänglig på Orexos hemsida (www.orexo.se)." This indicates the primary purpose of this short document is to announce the availability of a more detailed presentation regarding the M&A activity. Since the document itself is an announcement pointing to an attached presentation detailing strategy, financials, and the transaction, it fits the definition of an Investor Presentation (IP) being made available, or more accurately, an announcement about the publication of that presentation. Given the content heavily details the transaction, valuation, synergy quantification, and product portfolio review, it is strongly related to M&A Activity (TAR) or Investor Presentation (IP). However, the document explicitly states it is an *update* via an *attached presentation* about a *planned acquisition*. The core subject is the M&A transaction (TAR). Since the document is short (4394 chars) and announces the availability of a detailed presentation about the transaction, it could be RPA. But because the subject matter is so specific (M&A/Takeover), TAR is a strong candidate if the attached presentation is the main focus. If we treat the announcement itself as the primary document type, and it details a major corporate transaction (M&A), it falls under TAR (Merger Proposals/Takeover Bids). If the attached document is the Investor Presentation, then IP is relevant. Given the context of a major acquisition update, TAR is the most specific fit for the *subject matter* being announced. However, following Rule 2 (Menu vs Meal), since this is a short announcement pointing to an attached presentation, RPA (Report Publication Announcement) is technically correct for the *format* of this specific text. Since the content is a detailed update on a takeover bid, and the update is delivered via a presentation, I will classify it as an Investor Presentation (IP) as the content strongly aligns with what an IP covers (product portfolio, clinical data, synergy quantification, valuation), even though this specific text is the announcement wrapper. If IP wasn't an option, RPA would be the fallback for the wrapper. Given IP is an option, and the content is a detailed review of the acquired asset and transaction rationale, IP is the best fit for the substance being delivered.
2007-10-26 Swedish
M&A Activity 2007
M&A Activity Classification · 95% confidence The document is a press release dated October 26, 2007, providing an update on the planned acquisition of Biolipox by Orexo. It explicitly states: 'Orexo is today releasing further information pertaining to its planned acquisition of Biolipox through an updated presentation (please see attachment).' This indicates the primary purpose of this short document is to announce the availability of a more detailed presentation regarding a corporate transaction (M&A). Since the document itself is an announcement pointing to an attached presentation about a merger/takeover, it strongly aligns with the 'M&A Activity' (TAR) category, which covers merger proposals and takeover bids. Although it announces a presentation, the core subject matter is the M&A transaction itself, making TAR more specific than RPA or RNS. The transaction involves issuing shares, which touches upon 'SHA' or 'CAP', but the overarching theme is the acquisition (TAR). Given the context of a major corporate transaction update, TAR is the most appropriate classification.
2007-10-26 English
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is titled "Pressmeddelande" (Press Release) and announces a specific business event: Orexo signing a distribution agreement with Hospira for the pain product Rapinyl® in Asian markets. This type of announcement, detailing strategic partnerships, licensing deals, or significant commercial agreements, typically falls under corporate actions or general business updates. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since it details a significant commercial transaction (distribution/licensing rights), it is best classified as a general corporate announcement. Given the provided options, 'Regulatory Filings' (RNS) is the most appropriate fallback for significant, non-standardized corporate news that doesn't fit the other specific categories like M&A (TAR) or Financing (CAP). However, since the core content is a commercial agreement, and there is no specific code for 'Commercial Agreement', RNS serves as the best fit among the available choices for a general, material announcement.
2007-10-25 Swedish
Regulatory Filings 2007
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Press release October 25, 2007" and details a significant business event: Orexo signing a distribution agreement with Hospira for a product in Asia. This type of announcement, focusing on strategic business developments, partnerships, or material corporate news outside of mandatory financial reporting (like 10-K or ER), is best classified as a general Regulatory Filing (RNS) or potentially a specific announcement if one fits better. Since it is a press release announcing a commercial agreement, and there is no specific category for 'Commercial Agreement Announcement', RNS (Regulatory Filings / General Announcement) is the most appropriate fallback. It is not an Earnings Release (ER), Annual Report (10-K), or a Call Transcript (CT). It is not a Director's Dealing (DIRS) or a Capital/Financing Update (CAP). Therefore, RNS is the best fit for a general corporate press release.
2007-10-25 English
Interim / Quarterly Report 2007
Interim / Quarterly Report Classification · 100% confidence The document is a 'delårsrapport' (interim report) for Orexo AB covering the period January-September 2007. It contains detailed financial statements, including income statements, balance sheet summaries, and management commentary on business performance, product development, and market strategy. As it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. 9M 2007
2007-10-23 Swedish
Interim / Quarterly Report 2007
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January - September 2007' and contains detailed financial statements, including income statements, key events, and operational updates for the specified period. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2007
2007-10-23 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.